Literature DB >> 28852833

Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland.

Agnieszka Kalinska-Bienias1, Katarzyna Lukowska-Smorawska2, Pawel Jagielski3, Cezary Kowalewski2, Katarzyna Wozniak2.   

Abstract

Bullous pemphigoid (BP) is associated with higher mortality and coexisting comorbidities, some of them affecting poor prognosis. The aim of the study was to identify prognostic factors causing greater mortality both in the 1st and 3rd year of follow-up and to determine the 1-, 2-, 3-year mortality rates, standardized mortality ratio (SMR) in Polish BP patients. All patients with BP (a cohort of 205 patients, mean age 76.2 years) diagnosed between 5 January 2000 and 10 December 2013 in a referral unit for autoimmune bullous diseases at the university hospital in Poland were included retrospectively. Mortality data were obtained from the Centre for Document Personalization at the Minister of Interior and Administration. Our original observation was that prednisone in moderate dose (0.5 mg kg-1) in monotherapy was an independent risk factor of fatal prognosis in the 1st year of follow-up, assessed using multivariate analysis. We confirmed the strong correlation between neurological diseases and greater mortality. Both in the 1st and 3rd year of follow-up, dementia and Parkinson disease resulted in increased mortality. We also found that arrhythmias significantly increased mortality in the 1st and 3rd year of follow-up. The prognostic factors in BP changed over time of follow-up. In the 3rd year of observation, the age above 77, longer hospitalization and BP severity were associated with greater mortality. We observed poorer prognosis in BP patients than age-matched general Polish population. The 1-, 2-, 3-year mortality rates were 22.4, 31.2, 39.5% and SMR was 3.8 (95% CI 3.4-3.7).

Entities:  

Keywords:  Bullous pemphigoid; Epidemiology; Mortality; Prednisone; Prognostic factors; Standardized mortality ratio

Mesh:

Year:  2017        PMID: 28852833     DOI: 10.1007/s00403-017-1772-x

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  8 in total

1.  Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study.

Authors:  Yun-Ju Tsai; Yung-Tsu Cho; Chia-Yu Chu
Journal:  Am J Clin Dermatol       Date:  2022-05-17       Impact factor: 6.233

2.  Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.

Authors:  Aniek Lamberts; H Ilona Euverman; Jorrit B Terra; Marcel F Jonkman; Barbara Horváth
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

Review 3.  Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature.

Authors:  Rikke Bech; Line Kibsgaard; Christian Vestergaard
Journal:  Front Med (Lausanne)       Date:  2018-09-04

Review 4.  Depression and Anxiety in Patients with Bullous Pemphigoid: Impact and Management Challenges.

Authors:  Nicolas Kluger; Anna Pankakoski; Jaana Panelius
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-01-21

5.  Prognostic factors for mortality in bullous pemphigoid: A systematic review and meta-analysis.

Authors:  Xianxia Chen; Yaqiang Zhang; Zhicheng Luo; Yujuan Wu; Taoxiang Niu; Jiayuan Zheng; Yuanyuan Xie
Journal:  PLoS One       Date:  2022-04-15       Impact factor: 3.752

Review 6.  IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review.

Authors:  Ariadne Hadjikyriacou Saniklidou; Patrick J Tighe; Lucy C Fairclough; Ian Todd
Journal:  Arch Dermatol Res       Date:  2017-10-25       Impact factor: 3.017

7.  Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies.

Authors:  Luca Petricca; Maria Rita Gigante; Annamaria Paglionico; Stefano Costanzi; Gisella Vischini; Clara Di Mario; Valentina Varriano; Giacomo Tanti; Barbara Tolusso; Stefano Alivernini; Giuseppe Grandaliano; Gianfranco Ferraccioli; Elisa Gremese
Journal:  Front Med (Lausanne)       Date:  2020-10-28

Review 8.  Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Authors:  Tong Zhou; Bin Peng; Songmei Geng
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.